• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by TriSalus Life Sciences Inc.

    4/25/25 5:20:53 PM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email
    S-8 1 tm2513131d3_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on April 25, 2025

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    TRISALUS LIFE SCIENCES, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware 85-3009869
    (State or other jurisdiction of incorporation or organization) (I.R.S Employer Identification No.)

     

    6272 W. 91st Ave.

    Westminster, Colorado

    80031
    (Address of Principal Executive Offices) (Zip Code)

     

     

     

    TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan

    TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan

    (Full Title of the Plan)

     

     

     

    Mary Szela

    Chief Executive Officer

    6272 W. 91st Ave.

    Westminster, Colorado 80031

    (Name and address of agent for service)

     

    Tel: (303) 426 -1222

    (Telephone number, including area code, of agent for service)

     

     

     

    Copy to:

     

    Matt Browne

    Carlos Ramirez

    Cooley LLP

    10265 Science Center Drive

    San Diego, California 92121

    (858) 550-6000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
          Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

      

    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E 

     

    This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the registrant on Form S-8 relating to the same employee benefit plans is effective.

     

    The registrant previously registered shares of its Common Stock for issuance under the registrant’s 2023 Equity Incentive Plan (the “2023 EIP”) and 2023 Employee Stock Purchase Plan (the “2023 ESPP”) under Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on October 16, 2023 (File No. 333-275009) and April 11, 2024 (File No. 333-3278627) (collectively, the “Prior Registration Statements”). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Prior Registration Statements.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the registrant with the Commission are hereby incorporated by reference in this registration statement (in each case excluding any information furnished and not filed according to applicable rules, such as information furnished pursuant to Item 2.02 or Item 7.01 on any Current Report on Form 8-K):

     

    (a)    the registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on April 15, 2025;

     

    (b)    the registrant’s Current Reports on Form 8-K filed with the Commission on January 8, 2025, January 31, 2025, February 19, 2025, February 25, 2025, April 17, 2025 and April 23, 2025; and

     

    (c) the description of the registrant’s securities contained in the Registration Statement on Form 8-A filed with the Commission on December 16, 2020, as updated by Exhibit 4.4 to the registrant’s Current Report on Form 8-K filed with the Commission on August 16, 2023 and by Exhibit 4.7 to the registrant’s Quarterly Report on Form 10-Q filed with the Commission on August 14, 2024, and, as well as any additional amendments or reports filed with the Commission for the purpose of updating the description.

     

    All reports and other documents filed by the registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than current reports furnished under Item 2.02 and Item 7.01 of Form 8-K and any exhibits furnished on such form that relate to such items, after the date of this Registration Statement, and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

      

     

     

      

    Item 8. Exhibits.

     

    Exhibit
    No.
      Description
    4.1   Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on August 16, 2023).
    4.2   Amended and Restated Bylaws of TriSalus Life Sciences, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed on August 16, 2023).
    4.3   Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on August 16, 2023).
    5.1*   Opinion of Cooley LLP.
    23.1*   Consent of KPMG LLP, independent registered public accounting firm.
    23.2*   Consent of Grant Thornton LLP, independent registered public accounting firm.
    23.3*   Consent of Cooley LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (contained on the signature page hereto).
    99.1   TriSalus Life Sciences, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.21 to the Current Report on Form 8-K filed on August 16, 2023).
    99.2   TriSalus Life Sciences, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.24 to the Current Report on Form 8-K filed on August 16, 2023).
    99.3   Form of Stock Option Grant Notice and Form of Stock Option Agreement under 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.22 to the Current Report on Form 8-K filed on August 16, 2023).
    99.4   Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Agreement under 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.23 to the Current Report on Form 8-K filed on August 16, 2023).
    107*   Filing Fee Table.

      

     

    * Filed herewith.

      

     

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Westminster, State of Colorado, on April 25th, 2025.

     

      TRISALUS LIFE SCIENCES, INC.
       
      By: /s/ Mary Szela
        Mary Szela
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mary Szela and James Young, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Mary Szela   Chief Executive Officer, President and Director   April 25, 2025
    Mary Szela   (Principal Executive Officer)    
             
    /s/ James E. Young   Chief Financial Officer   April 25, 2025
    James E. Young   (Principal Financial and Accounting Officer)    
             
    /s/ Mats Wahlström   Chairman of the Board of Directors   April 25, 2025
    Mats Wahlström        
             
    /s/ Arjun Desai   Director   April 25, 2025
    Arjun Desai        
             
    /s/ Andrew von Eschenbach   Director   April 25, 2025
    Andrew von Eschenbach        
             
    /s/ Gary Gordon   Director   April 25, 2025
    Gary Gordon        
             
    /s/ Kerry Hicks   Director   April 25, 2025
    Kerry Hicks        
             
    /s/ David J. Matlin   Director   April 25, 2025
    David J. Matlin        
             
    /s/ Sean Murphy   Director   April 25, 2025
    Sean Murphy        
             
    /s/ William Valle   Director   April 25, 2025
    William Valle        

     

     

    Get the next $TLSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief of Research Cox Bryan F. was granted 40,000 shares, increasing direct ownership by 32% to 166,599 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    11/25/25 4:15:56 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Chief of Clinical Operations Devlin Jodi was granted 50,000 shares, increasing direct ownership by 99% to 100,571 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    11/25/25 3:56:02 PM ET
    $TLSI
    Medical Specialities
    Health Care

    CEO and President Szela Mary T was granted 550,000 shares, increasing direct ownership by 285% to 742,802 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    11/25/25 3:55:07 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

    Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62 million TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year

    1/12/26 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and current treatment landscape for symptomatic thyroid disease. To register, click here. The event will provide an overview of the TriNav Infusion System and its Pressure-Enabled Delivery for Thyroid Artery Embolization (PED-TAE) approach. PED

    12/4/25 4:01:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/6/25 6:09:01 PM ET
    $TLSI
    Medical Specialities
    Health Care

    CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    1/31/25 5:54:39 PM ET
    $TLSI
    Medical Specialities
    Health Care

    CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    1/29/25 6:15:05 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    SEC Filings

    View All

    TriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    2/9/26 8:59:49 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/12/26 7:09:19 AM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form EFFECT filed by TriSalus Life Sciences Inc.

    EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    12/5/25 12:15:29 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on TriSalus Life Sciences

    Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

    2/13/25 8:48:50 AM ET
    $TLSI
    Medical Specialities
    Health Care

    Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

    Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

    12/17/24 8:31:30 AM ET
    $TLSI
    Medical Specialities
    Health Care

    ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

    ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

    11/11/24 7:48:55 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (University Radiology Group, Rutgers Robert Wood Johnson University Hospital), who will join company management to discuss the unmet need and current treatment landscape for uterine fibroids. To register, click here. The event will provide an over

    11/10/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

    David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effec

    5/30/25 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Financials

    Live finance-specific insights

    View All

    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

    Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62 million TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year

    1/12/26 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

    TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enables Safe, Effective Thyroid Embolization Alternative to Surgery Reaffirmed revenue guidance of at least 50% growth due to continued commercial momentum Hosting Conference Call and Webcast today at 4:30pm ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and pr

    11/13/25 4:01:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

    Conference Call and Webcast Scheduled for Thursday November 13, 2025 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in det

    10/30/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    12/4/24 4:00:06 PM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    10/21/24 8:25:05 AM ET
    $TLSI
    Medical Specialities
    Health Care